FindTrial
Sign In

Comparing the Ketogenic Effect of Coconut Oil and Different MCTs

Comparing the Ketogenic Effect of Coconut Oil and Different Medium-chain Triglycerides

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02679222
Acronym
MCT-Coco
Enrollment
10
Registered
2016-02-10
Start date
2015-06-30
Completion date
2017-03-01
Last updated
2020-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adults

Keywords

Ketones, Coconut oil, Medium Chain Triglycerides

Brief summary

The aim of this study is to compare the ketogenic effect of coconut oil and three MCT oils (60-40 , tricaprylin and triheptanoate) on the production of ketones in healthy adults. Each oil are evaluated individually or in combination over a 8h-period during which repeated blood sampling is performed.

Detailed description

The study is composed of eight successive visits. Each visit consists of the consumption of one individual oil or a mixture of oils (20 g of coconut oil or 10 g of coconut oil + 10 g of MCT 60-40 or 20 g MCT 60-40 or 10 g coconut oil + 10 g tricaprylin or 20 g tricaprylin or 10 g coconut oil + 10 g triheptanoate or 20 g triheptanoate) and a 8h follow-up during which repeated blood samples are taken for laboratory analysis (plasma beta-hydroxybutyrate, acetoacetate, glucose, free fatty acids, triglycerides, total cholesterol, lactate and insulin).

Interventions

DIETARY_SUPPLEMENTCoconut oil

20 g of coconut oil

DIETARY_SUPPLEMENTCoconut oil + MCT

10 g of coconut oil + 10 g of MCT (60 of C8 + 40 of C10)

DIETARY_SUPPLEMENTMCT

20 g of MCT (60 of C8+40 of C10)

DIETARY_SUPPLEMENTCoconut oil + tricaprylin

10 g coconut oil + 10 g tricaprylin

DIETARY_SUPPLEMENTTricaprylin

20 g tricaprylin

DIETARY_SUPPLEMENTTricaprin

20 g tricaprin

DIETARY_SUPPLEMENTControl

No supplement taken on this visit

Sponsors

Université de Sherbrooke
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Healthy adult over 18 y old.

Exclusion criteria

* Fasting plasma glucose ≥7.0 mM (diabetics or pre-diabetics); * Smoking * Clinically-significant gastro-intestinal disease/conditions. * Clinically-significant liver disease/dysfunction. * Clinically-significant cardiac disease/conditions. * Clinically-significant abnormal coagulation. * Taking a medication that could affect lipid and glucose metabolism * Hypertension * Pregnancy or breastfeeding * Exercising more than 3 times a week

Design outcomes

Primary

MeasureTime frameDescription
Plasma Ketone Concentrations8 hoursTotal ketones = Plasma acetoacetate (µmol/L) + beta-hydroxybutyrate (µmol/L) measured over a 8 hour period (i.e. daily mean). Samples are taken every 30 minutes on a 8 hours period. The mean is reported here.

Secondary

MeasureTime frameDescription
Plasma Acetoacetate/Beta-hydroxybutyrate Ratio8 hoursPlasma ratio of acetoacetate (µmol/L)/ beta-hydroxybutyrate (µmol/L) measured over a 8 hour period (i.e area-under-the-curve over 8 hours).

Countries

Canada

Participant flow

Participants by arm

ArmCount
Supplementation
Protocol involved seven separate but identical metabolic study days for each participant. the test substances were evaluated in random order: vehicle (Control) or 20 mL of the test oils (Coconut oil; tricaprin; tricaprylin; MCT \[tricaprylin/tricaprin\]; coconut oil + MCT \[50:50\]; Coconut oil + tricaprylin \[50:50\]) taken twice, once at breakfast and once at mid-day. Coconut oil: 20 g of coconut oil Coconut oil + MCT: 10 g of coconut oil + 10 g of MCT (60 of C8 + 40 of C10) MCT: 20 g of MCT (60 of C8+40 of C10) Coconut oil + tricaprylin: 10 g coconut oil + 10 g tricaprylin Tricaprylin: 20 g tricaprylin Tricaprin: 20 g tricaprin Control: No supplement taken on this visit
9
Total9

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyNo time for project1

Baseline characteristics

CharacteristicSupplementation—
Age, Continuous34 years
STANDARD_DEVIATION 12
—
Body mass index24 kg/m^2
STANDARD_DEVIATION 3
—
Glucose4.3 mmol/L
STANDARD_DEVIATION 0.2
—
Ketones90 µmol/L
STANDARD_DEVIATION 61
—
Race and Ethnicity Not Collected—— Participants
Region of Enrollment
Canada
9 Participants—
Sex: Female, Male
Female
4 Participants—
Sex: Female, Male
Male
5 Participants—

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 9
serious
Total, serious adverse events
0 / 9

Outcome results

Primary

Plasma Ketone Concentrations

Total ketones = Plasma acetoacetate (µmol/L) + beta-hydroxybutyrate (µmol/L) measured over a 8 hour period (i.e. daily mean). Samples are taken every 30 minutes on a 8 hours period. The mean is reported here.

Time frame: 8 hours

ArmMeasureValue (MEAN)Dispersion
ControlPlasma Ketone Concentrations69 µmol/LStandard Deviation 92
Medium Chain TriglyceridePlasma Ketone Concentrations294 µmol/LStandard Deviation 85
TricaprinPlasma Ketone Concentrations109 µmol/LStandard Deviation 41
TricaprylinPlasma Ketone Concentrations363 µmol/LStandard Deviation 109
Coconut OilPlasma Ketone Concentrations107 µmol/LStandard Deviation 97
Coconut Oil + MCTPlasma Ketone Concentrations141 µmol/LStandard Deviation 39
Coconut Oil + TricaprylinPlasma Ketone Concentrations235 µmol/LStandard Deviation 79
Secondary

Plasma Acetoacetate/Beta-hydroxybutyrate Ratio

Plasma ratio of acetoacetate (µmol/L)/ beta-hydroxybutyrate (µmol/L) measured over a 8 hour period (i.e area-under-the-curve over 8 hours).

Time frame: 8 hours

ArmMeasureValue (MEAN)Dispersion
ControlPlasma Acetoacetate/Beta-hydroxybutyrate Ratio7.7 RatioStandard Deviation 3.2
Medium Chain TriglyceridePlasma Acetoacetate/Beta-hydroxybutyrate Ratio6.9 RatioStandard Deviation 1.5
TricaprinPlasma Acetoacetate/Beta-hydroxybutyrate Ratio7.7 RatioStandard Deviation 1.1
TricaprylinPlasma Acetoacetate/Beta-hydroxybutyrate Ratio5.9 RatioStandard Deviation 1
Coconut OilPlasma Acetoacetate/Beta-hydroxybutyrate Ratio9.5 RatioStandard Deviation 2.9
Coconut Oil + MCTPlasma Acetoacetate/Beta-hydroxybutyrate Ratio8.4 RatioStandard Deviation 1.3
Coconut Oil + TricaprylinPlasma Acetoacetate/Beta-hydroxybutyrate Ratio8.1 RatioStandard Deviation 2.2

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026